228 related articles for article (PubMed ID: 9855623)
1. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets.
Friebe A; Müllershausen F; Smolenski A; Walter U; Schultz G; Koesling D
Mol Pharmacol; 1998 Dec; 54(6):962-7. PubMed ID: 9855623
[TBL] [Abstract][Full Text] [Related]
2. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells.
Schmidt K; Schrammel A; Koesling D; Mayer B
Mol Pharmacol; 2001 Feb; 59(2):220-4. PubMed ID: 11160856
[TBL] [Abstract][Full Text] [Related]
4. Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide.
Hoenicka M; Becker EM; Apeler H; Sirichoke T; Schröder H; Gerzer R; Stasch JP
J Mol Med (Berl); 1999 Jan; 77(1):14-23. PubMed ID: 9930922
[TBL] [Abstract][Full Text] [Related]
5. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.
Mülsch A; Bauersachs J; Schäfer A; Stasch JP; Kast R; Busse R
Br J Pharmacol; 1997 Feb; 120(4):681-9. PubMed ID: 9051308
[TBL] [Abstract][Full Text] [Related]
6. The vasodilator-stimulated phosphoprotein (VASP): target of YC-1 and nitric oxide effects in human and rat platelets.
Becker EM; Schmidt P; Schramm M; Schröder H; Walter U; Hoenicka M; Gerzer R; Stasch JP
J Cardiovasc Pharmacol; 2000 Mar; 35(3):390-7. PubMed ID: 10710123
[TBL] [Abstract][Full Text] [Related]
7. Synergism between nitric oxide and hydrogen peroxide in the inhibition of platelet function: the roles of soluble guanylyl cyclase and vasodilator-stimulated phosphoprotein.
Sabetkar M; Naseem KM; Tullett JM; Friebe A; Koesling D; Bruckdorfer KR
Nitric Oxide; 2001 Jun; 5(3):233-42. PubMed ID: 11384196
[TBL] [Abstract][Full Text] [Related]
8. Interference of neutrophil-platelet interaction by YC-1: a cGMP-dependent manner on heterotypic cell-cell interaction.
Liao CH; Cheng JT; Teng CM
Eur J Pharmacol; 2005 Sep; 519(1-2):158-67. PubMed ID: 16112105
[TBL] [Abstract][Full Text] [Related]
9. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
10. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.
Galle J; Zabel U; Hübner U; Hatzelmann A; Wagner B; Wanner C; Schmidt HH
Br J Pharmacol; 1999 May; 127(1):195-203. PubMed ID: 10369473
[TBL] [Abstract][Full Text] [Related]
11. YC-1, a novel activator of platelet guanylate cyclase.
Ko FN; Wu CC; Kuo SC; Lee FY; Teng CM
Blood; 1994 Dec; 84(12):4226-33. PubMed ID: 7527671
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of YC-1-induced activation of soluble guanylyl cyclase.
Friebe A; Koesling D
Mol Pharmacol; 1998 Jan; 53(1):123-7. PubMed ID: 9443939
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272.
Mullershausen F; Russwurm M; Friebe A; Koesling D
Circulation; 2004 Apr; 109(14):1711-3. PubMed ID: 15066950
[TBL] [Abstract][Full Text] [Related]
14. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
[TBL] [Abstract][Full Text] [Related]
15. Synergistic phosphorylation of the focal adhesion-associated vasodilator-stimulated phosphoprotein in intact human platelets in response to cGMP- and cAMP-elevating platelet inhibitors.
Nolte C; Eigenthaler M; Horstrup K; Hönig-Liedl P; Walter U
Biochem Pharmacol; 1994 Oct; 48(8):1569-75. PubMed ID: 7980622
[TBL] [Abstract][Full Text] [Related]
16. An evolutionarily conserved mechanism for sensitization of soluble guanylyl cyclase reveals extensive nitric oxide-mediated upregulation of cyclic GMP in insect brain.
Ott SR; Delago A; Elphick MR
Eur J Neurosci; 2004 Sep; 20(5):1231-44. PubMed ID: 15341595
[TBL] [Abstract][Full Text] [Related]
17. Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change.
Jensen BO; Kleppe R; Kopperud R; Nygaard G; Døskeland SO; Holmsen H; Selheim F
Platelets; 2011; 22(1):8-19. PubMed ID: 20958117
[TBL] [Abstract][Full Text] [Related]
18. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies.
Aktas B; Utz A; Hoenig-Liedl P; Walter U; Geiger J
Stroke; 2003 Mar; 34(3):764-9. PubMed ID: 12624305
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of platelet adhesion to collagen by cGMP-elevating agents.
Wu CC; Ko FN; Teng CM
Biochem Biophys Res Commun; 1997 Feb; 231(2):412-6. PubMed ID: 9070290
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet effect of AMP-activated protein kinase activator and its potentiation by the phosphodiesterase inhibitor dipyridamole.
Liu Y; Oh SJ; Chang KH; Kim YG; Lee MY
Biochem Pharmacol; 2013 Oct; 86(7):914-25. PubMed ID: 23876340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
